Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Catalyst Pharmaceutical Inc (CPRX) Com Stk USD0.001

Sell:$4.00 Buy:$4.93 Change: $0.01 (0.21%)
NASDAQ:0.52%
Market closed |  Prices as at close on 2 July 2020 | Switch to live prices |
Sell:$4.00
Buy:$4.93
Change: $0.01 (0.21%)
Market closed |  Prices as at close on 2 July 2020 | Switch to live prices |
Sell:$4.00
Buy:$4.93
Change: $0.01 (0.21%)
Market closed |  Prices as at close on 2 July 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Contact details

Address:
355 Alhambra Cir Ste 1250
CORAL GABLES
33134-5038
United States
Telephone:
+1 (305) 5292522
Website:
https://catalystpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CPRX
ISIN:
US14888U1016
Market cap:
$498.46 million
Shares in issue:
103.42 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Patrick McEnany
    Chairman of the Board, President, Chief Executive Officer
  • Alicia Grande
    Chief Financial Officer, Vice President, Treasurer
  • Steven Miller
    Chief Operating Officer, Chief Scientific Officer
  • Brian Elsbernd
    Chief Compliance Officer, Chief Legal Officer
  • Jeffrey Del Carmen
    Chief Commercial Officer
  • Gary Ingenito
    Chief Medical Officer and Head of Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.